| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $400,000 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Ben-Noon Alon | Chief Executive Officer | 1 | $200,000 | 0 | $0 | $200,000 |
| Eisenberg Or | Chief Financial Officer | 1 | $200,000 | 0 | $0 | $200,000 |
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and …
Over the last 12 months, insiders at NeuroSense Therapeutics Ltd. have bought $400,000 and sold $0 worth of NeuroSense Therapeutics Ltd. stock.
On average, over the past 5 years, insiders at NeuroSense Therapeutics Ltd. have bought $400,000 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ben-Noon Alon (Chief Executive Officer) — $200,000. Eisenberg Or (Chief Financial Officer) — $200,000.
The last purchase of 250,000 shares for transaction amount of $200,000 was made by Ben-Noon Alon (Chief Executive Officer) on 2026‑06‑16.
| 2026-06-16 | Ben-Noon Alon | Chief Executive Officer | 250,000 1.16% | $0.80 | $200,000 | -41.20% | ||
| 2026-06-16 | Eisenberg Or | Chief Financial Officer | 250,000 1.16% | $0.80 | $200,000 | -41.20% |
| Increased Positions | 8 | +80% | 213,058 | +76.66% |
| Decreased Positions | 3 | -30% | 144,849 | -52.12% |
| New Positions | 5 | New | 164,692 | New |
| Sold Out Positions | 2 | Sold Out | 67,400 | Sold Out |
| Total Postitions | 15 | +50% | 346,134 | +24.54% |